Ras proteins are small GTPases playing a pivotal role in cell proliferation and differentiation. Their activation depends on the competing action of GTPase activating proteins and guanine nucleotide exchange factors (GEF). The properties of two dominant-negative mutants within the catalytic domains of the ras-specific GEF, CDC25
Ras proteins are highly conserved guanine nucleotide proteins, endowed with intrinsic low GTPase activity (1) . Ras proteins act as molecular switches that couple membranebound receptors to intracellular signaling pathways controlling cell growth and differentiation. Within cells, ras proteins exist in either a GTP-bound ("on" state) or a GDP-bound ("off" state) form. The level of the active, GTP-bound form results from the balance of the competing activity of GTPase activating proteins and guanine nucleotide exchange factors (GEF) 1 (reviewed in Refs. [1] [2] [3] [4] . Oncogenic versions of p21 ras are found mostly in the GTP-bound form either because of a reduced GTPase activity or because of an increased GDP/GTP exchange.
The prototypes of ras-specific GEFs are the product of the yeast CDC25 gene (6) and its close homologue SDC25 (7), the first protein of this class for which ras-specific GEF activity was demonstrated (8) . Two ras-specific GEF classes have been identified in mammalian cells. One class, whose cDNA was originally isolated by functional complementation of a cdc25 mutant of Saccharomyces cerevisiae, has been called CDC25 Mm and is mostly brain-specific (9, 10) . Human and rat CDC25 Mm homologues have also been isolated (11, 12) . The other class, Sos-GEF, has been isolated on the basis of homology with the Son of Sevenless gene of Drosophila melanogaster (13) and is expressed ubiquitously. Both GEFs are large, multi-domain proteins; despite their different structural organization, the two catalytic domains are approximately 70% homologous. The differences in structural organization reflect the involvement in different signal transduction pathways. Sos has been shown to work downstream of tyrosine kinase receptors (14, 15) whereas CDC25
Mm may interact with trimeric G protein-coupled receptors (16, 17) . More recently a role for CDC25
Mm in synaptic transmission and long-term memory has been proposed (18) . CDC25
Mm has been shown to be affected by calcium levels (19, 20) . Deregulated expression of either a full-length GEF or its catalytic domain has been shown to induce cell transformation in different experimental systems (21) (22) (23) .
The GEF⅐ras cycle has been studied extensively in recent years. Mutational analysis of residues involved in GEF⅐ras interactions gave insights on the role of ras residues involved in interaction with GEF molecules (24 -27) , although much less information was available on the involved GEF residues (28 -30) . Only in the last year, however, have a detailed kinetic analysis of the GEF⅐ras cycle (31) and the structure of a ras⅐GEF complex (32) been published, setting the basis for a clearer understanding of the complex molecular events responsible for ras activation by guanine nucleotide exchange factors. Dominant-negative mutants in small G proteins have become increasingly popular as tools in signal transduction studies. However, very few dominant-negative exchange factors have been described so far. One class comprises GEF molecules deleted in their catalytic domains, and their dominant-negative properties are most likely due to non-productive binding to upstream regulators, which results in interruption of signal transmission and failure to activate ras. This kind of mutant has been described in both Sos (33) and CDC25 Mm (17) . A second and potentially more interesting dominant-negative class comprises mutants in the catalytic domain that are still able to bind ras but are unable to induce guanine nucleotide exchange. So far only one mutant of this class has been described in the yeast GEF CDC25, with the only evidence for this mutant acting as a dominant-negative mutant being an approximately 2-fold reduction in growth rate in yeast overexpressing the mutant CDC25 (30) .
Here we show that the mutations of either tryptophan 1056 or threonine 1184 in CDC25
Mm , two residues which, on the basis of the published structure of the Sos⅐p21 ras complex (32) , are located at the interface with ras in proximity of its nucleotide-binding site, yield molecules with dominant-negative properties. Both mutants are catalytically inactive, bind ras with great avidity, and form a stable complex in vitro even in the presence of excess nucleotide, a condition where little, if any, complex is formed by ras with wild-type GEF. Expression in vivo of the GEFs down-regulates the ras pathway both in mouse fibroblasts (as determined by inhibition of the expression of a ras-responsive fos-luciferase promoter) and in vascular smooth muscle cells in which growth rate and DNA synthesis (events known to be ras-dependent) are severely inhibited by expression of one of the two mutants. The two mutants may be useful both as tools for the study of the ras signal transduction pathway and as lead compounds to develop drugs that are able to down-regulate signal transduction.
EXPERIMENTAL PROCEDURES
Recombinant and Genetic Manipulations-Recombinant DNA manipulations were performed according to standard methods (34) . The complete CDC25
Mm protein was expressed in NIH3T3 cells using the pcDNA3 plasmid (Invitrogen) under the control of the cytomegalovirus promoter. Site-directed mutagenesis of CDC25
Mm codon 1056 was performed on the 3Ј-terminal region of the wild-type CDC25
Mm gene (encoding residues 976 -1262 of the mature protein) cloned in the pAL-TER™ vector (Promega), using the following mutagenic primers: CDC25
MmW1056A , 5Ј-TT GGC CAG GGC GCG ATG AAG GCC GA-3Ј; CDC25 MmW1056E , 5Ј-TT GGC CAG GGC GAG ATG AAG GCC GA-3Ј; CDC25 MmW1056F , 5Ј-TT GGC CAG GGC TTC ATG AAG GCC GA-3Ј; CDC25 MmW1056K , 5Ј-TT GGC CAG GGC AAG ATG AAG GCC GA-3Ј; and CDC25
MmW1056L , 5Ј-TT GGC CAG GGC TTG ATG AAG GCC GA-3Ј. The full-length gene was then reconstructed in pcDNA3 for expression in mammalian cells. Mutagenesis of codon 1184 was effected using the Quick-Change™ site-directed mutagenesis kit (Stratagene) using the following complementary oligonucleotides (5Ј-C CTG GGG ATG TAT CTC GAG GAC TTG GTG TTC ATC G-3Ј and 5Ј-C GAT GAA CAC CAA GTC CTC GAG ATA CAT CCC CAG G-3Ј) directly in pcDNA3-based plasmids. In all oligonucleotides, the mutant codons are shown in bold type. The catalytic domains (residues 976 -1262) of all mutants were cloned into pGEX2T vector (Amersham Pharmacia Biotech), as described previously for the wild-type protein (9) , for expression in Escherichia coli and in yeast shuttle vectors (pCYM or pVTU) for cdc25 complementation assays (35, 36) . Yeast media, manipulations, and transformations (37, 38) were as described.
CDC25
Mm PCR from A10 Genomic DNA and CDC25 Mm RT-PCRGenomic DNA was prepared from several clones of A10 rat embryonic aortic smooth muscle cells transfected with recombinant pcDNA3 plasmid containing the mutant CDC25 MmW1056E gene according to published protocols (39) . 1 g of genomic DNA from each clone was used to amplify a CDC25 Mm internal fragment of about 800 base pairs. Briefly, the genomic DNA was amplified in 50 l of PCR reaction mixture containing 5 l of 10ϫ PCR buffer (Promega, Madison, WI), 3 l of 25 mM MgCl 2 (Promega, Madison, WI), 1 l of 2.5 mM stocks of dNTPs (Roche Molecular Biochemicals), 50 pmol of each primer (5Ј-CGT-GATCTGGTGGACAATAACCG-3Ј and 5Ј-TCGTCTGCTTAGAAACTT-TGAGCC-3Ј), and 0.5 units of Taq DNA polymerase (Promega, Madison WI). Cycling conditions included an initial denaturation step at 94°C for 5 min followed by 30 cycles of 94°C for 1 min, 50°C for 1 min, and 72°C for 2 min. The PCR reaction mixtures were separated and visualized in 1.5% agarose gel stained with ethidium bromide. Total cellular RNA was isolated from cells by the method of acid guanidium thiocyanate phenolchloroform extraction as previously described (39) . 5 g of total RNA from each sample were reverse-transcribed into first-strand cDNA using an RT-PCR kit (Stratagene, La Jolla, CA). Equal amounts of cDNAs were amplified using the same oligonucleotide primers and the same reaction conditions as described above with the only difference being the performance 40 cycles rather than 30.
Transfection of Mouse Fibroblasts and Determination of fos-luciferase Activity-NIH3T3 mouse fibroblasts were routinely grown in Dulbecco's modified Eagle's medium supplemented with 10% newborn calf serum, 100 units/ml penicillin, 100 g/ml streptomycin, and 2 mM glutamine. Cells were routinely transfected with 1 g of pcDNA3-derived plasmids by the LipofectAMINE reagent (Life Technologies, Inc.) method and cotransfected with 0.33 g of the ras-responsive fos-luciferase plasmid (21, 40) . In all transfections DNA was buffered with the empty pcDNA3 plasmid to a total of 1.5 g. After transfection, cells were starved for 24 h in serum-free medium supplemented with 4 g/ml transferrin and 10 Ϫ8 M sodium selenite and collected. When required, cells were stimulated for 16 -18 h with either 100 ng/ml PDGF or 20% newborn calf serum. Luciferase activity was assayed essentially as described (21) using the luciferase assay system with reporter lysis buffer (Promega) and normalized to protein content determined with the Bio-Rad Bradford kit.
Transfection of Smooth Muscle Cells and Determination of Cell Proliferation-A10
rat embryonic aortic smooth muscle cells (ATCC) were grown in Dulbecco's modified Eagle's medium supplemented with 20% fetal calf serum (Hyclone), 2 mM L-glutamine, and 50 g/ml gentamycin sulfate (Sigma). Smooth muscle cells (A10 cells) were transfected in 100-mm diameter Petri dishes at 50% confluence using 45 l/dish DOTAP liposomal transfection reagent (Roche Molecular Biochemicals). Each dish was transfected with 7.5 g of pcDNA3-derived plasmids. Following transfection, the cells were allowed to grow for 48 h and were then split and placed in normal growth media supplemented with 700 g/ml geneticin (G418, Sigma). After selection for two weeks, individual colonies were isolated and grown. All selected clones were grown in the presence of 700 g/ml G418. To perform morphological analysis, cells were plated 5 ϫ 10 3 /cm 2 and cultured in normal growth medium for 48 h. Cells were then washed twice with phosphate-buffered saline, fixed with methanol, and stained with Giemsa (Sigma). DNA synthesis was determined in quiescent cells (0.5% fetal calf serum for 31 h) by Protein Purification-Wild-type and mutant fusion proteins between glutathione S-transferase (GST) and CDC25 Mm 976 -1262 , ϳ58 kDa, were purified by glutathione-Sepharose chromatography (Amersham Pharmacia Biotech) as previously described (9, 41) . When required, glutathione-Sepharose-bound fusion proteins were cleaved with thrombin (Sigma) and further purified by ResourceQ (Amersham Pharmacia Biotech) chromatography essentially as described (42, 43) . Recombinant N-terminal His-tagged p21 ras protein was purified from an E. coli strain harboring a pQE™ (Qiagen, Valencia, CA)-derived plasmid according to the manufacturers instructions.
The binary complex ras⅐CDC25 Mm was made by incubating a 5-fold molar excess of p21 ras ⅐GDP in 50 mM Tris-Cl, pH 7.5, 10 mM MgCl 2 , 5 mM dithioerythritol buffer containing 10 mM EDTA with wild-type or mutant GST-GEF (pre-bound to glutathione-Sepharose) for 30 min at room temperature. The bound complex was washed extensively with phosphate-buffered saline, 14 mM ␤-mercaptoethanol, 1 mM EDTA, 0.5% Triton X-100. The complex was eluted with reduced glutathione (3 mg/ml in 50 mM Tris-Cl, pH 8.5, 50 mM NaCl, 14 mM ␤-mercaptoethanol, 1 mM EDTA, 0.5% Triton X-100), dialyzed against 50 mM Tris-Cl, pH 7.5, 50 mM NaCl, 14 mM ␤-mercaptoethanol, 50% glycerol), and stored at Ϫ20°C. At least 70% of the GST-GEF protein was bound to p21 ras under these conditions as judged by gel electrophoresis. Guanine Nucleotide Exchange and Dissociation Assays-The dissociation rate of the Ras-labeled guanine nucleotide complexes and the cold GDP to radioactively labeled GTP exchange reactions on p21 ras were measured by a nitrocellulose binding assay as described (41) . Briefly, the labeled complexes were prepared by incubating 1 M p21 ras protein in buffer A (50 mM Tris-Cl, pH7.5, 1 mM MgCl 2 , 100 mM NH 4 Cl, 1 mg/ml bovine serum albumin) for 10 min at 30°C with 3 mM EDTA and 20 M [ , Amersham Pharmacia Biotech). MgCl 2 (3 mM) was then added. The dissociation rate of these complexes (final concentration: 0.2 M in buffer A) was measured at 30°C after the addition of a 5000-fold excess of unlabeled nucleotide and the appropriate concentration of the wild-type or mutant exchange factor. For the cold GDP to [ 3 H]GTP exchange reaction, 0.2 M p21 ras proteins were incubated at 30°C in buffer A and the reaction was started by the addition of 2 M [ 3 H]GTP (7.0 Ci mmol
Ϫ1
). p21 ras -bound radioactivity was determined on 15 l-samples filtered through nitrocellulose discs (Millipore, 0.45 m) that were washed twice with 6 ml of ice-cold buffer A containing 10 mM MgCl 2 . The retained radioactivity was measured in a Packard liquid scintillation counter. In the standard dissociation and exchange assays, exchange factors were used at 1:10 molar ratio with p21 ras , i.e. at 0.02 M final concentration. For determination of noncatalytic dissociation rates, GEF concentration was raised up to 30-fold, i.e. at a 3:1 molar ratio with p21
ras .
Dissociation of the Nucleotide-free ras⅐GEF Complex by Guanine Nu-cleotides-Nucleotide dissociation of the p21
ras /GST-CDC25 Mm complexes was assayed as follows. 100 nM of each of the purified complexes was incubated with various nucleotide concentrations in 50 mM Tris-Cl, pH 7.5, 50 mM KCl, 5 mM MgCl 2 , and 5 mM ␤-mercaptoethanol at 4°C for 15 min and allowed to bind to glutathione-Sepharose beads. After extensive washing with phosphate-buffered saline, pH 7.4, the proteins bound to the beads were solubilized in sample buffer, separated by SDS-PAGE, transferred to nitrocellulose, and immunoblotted for the presence of p21 ras and CDC25 Mm to detect association of the p21 ras and CDC25
Mm proteins. Both anti-ras and anti-CDC25 Mm antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA). Peroxidase-conjugated secondary antibodies were from Zymed. Bound antibodies were visualized with ECL (Amersham Pharmacia Biotech).
Binding of Fluorescent Guanine Nucleotides to the Nucleotide-free ras⅐GEF-Guanine nucleotides carrying the N-methylanthraniloy (mant) group on ribose (mant nucleotides) were purchased from Molecular Probes (Eugene, OR). All measurements were carried out at 20°C in 50 mM Tris-Cl, pH 7.5, 10 mM MgCl 2 , and 5 mM dithioerythritol buffer using a Jasco FP-777 fluorometer with an excitation wavelength of 366 nm and an emission wavelength of 442 nm.
RESULTS

CDC25
MmW1056E and CDC25 MmT1184E in Vitro Induce Noncatalytic Dissociation of Ras-bound Nucleotides-One of our laboratories has been carrying out studies on structure/function relationships on a ras-specific GEF, CDC25
Mm , by sitedirected mutagenesis (44) . In this paper we report that tryptophan 1056, which is universally conserved in all ras-specific GEF, is essential for GEF activity. In fact its substitution with amino acid residues with different physico-chemical properties, namely alanine, lysine, glutamic acid, and leucine, originates inactive proteins based on complementation tests of the yeast cdc25 mutation. Only substitution with phenylalanine results in a partially active mutant that is able to complement the yeast cdc25 mutation (Table I ). The catalytic domain of each CDC25
Mm mutant was expressed in and purified from E. coli cells as a GST-fusion protein. All the mutant fusion proteins could be purified under the same conditions as the wild-type protein. All mutant fusion proteins were less soluble than wild-type protein, but retained the same electrophoretic mobility (data not shown). All mutant GEFs were unable to promote exchange even when added at a 3:1 molar ratio with p21 ras (Fig. 1A , close squares and data not shown). However, GEF W1056E was able to promote guanine nucleotide dissociation when added at a 3:1 ratio with p21 ras (Fig. 1B, close  squares) , a behavior expected for a dominant-negative mutant.
Another mutant with similar properties was revealed by mutation of threonine 1184 to glutamic acid. The GEF T1184E mutant was inactive in a cdc25 complementation assay (Table  I) and was unable to significantly stimulate guanine nucleotide exchange and dissociation when added in catalytic amounts (Fig. 1, A and B, open triangles) . Mutant GEF T1184E behaved similarly to GEF W1056E , because when used at a 3:1 ratio with p21 ras , GEF T1184E readily induced nucleotide dissociation but was unable to stimulate guanine nucleotide exchange (Fig. 1, B  and A, respectively, closed triangles) .
In a second series of experiments we tested whether the two mutants could compete with wild-type GEF. 200 nM p21 ras was charged with either labeled GDP or GTP nucleotide in the presence of 20 nM wild-type CDC25 Mm (Fig. 2, panels A and B,  respectively) . A 30-fold excess over wild-type GEF of the catalytic domain of either CDC25 MmW1056E or CDC25 MmT1184E was added (Fig. 2, A and B, closed squares and closed triangles,  respectively) . Under these conditions a rapid reduction of p21 ras -bound nucleotide, induced by wild-type CDC25 Mm , was observed. After ϳ10 min, the level of p21 ras -bound nucleotide reached a steady state level that remained constant for the time course of the experiment (1 h after addition of the mutant GEF). The effect is specifically due to the W1056E and T1184E mutations, because a similar experiment performed with the catalytic domain of the GEF W1056A mutant showed no significant drop in p21
ras -bound nucleotide (data not shown). In summary, these data indicate that GEF W1056E and GEF T1184E mutants are also able to effectively displace the bound nucleotide in the presence of wild-type GEF, thus showing properties typical of dominant-negative mutants.
Effect of Guanine Nucleotides on Dissociation of the p21
ras ⅐GEF Complex-We used mant-GDP (Fig. 3A) and mant-GTP (Fig. 3B ) to investigate binding of guanine nucleotides to mutant nucleotide-free ras⅐GEF complexes. A concentration as low as 25 nM of each nucleotide results in detectable specific binding of the nucleotide to the complex between nucleotide- 
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free ras and wild-type GEF. On the opposite, no detectable specific nucleotide binding to the complexes between nucleotide-free ras and either GEF W1056E or GEF T1184E was observed for nucleotide concentrations at least 10-fold higher. At nucleotide concentrations higher than 1 M the fluorescence contributed by nucleotide binding to the protein was so small in comparison to total fluorescence (less than 10%) that no reproducible data could be obtained for concentrations exceeding this level.
To analyze whether reduced nucleotide binding correlates with increased stability of the binary p21 ras ⅐GEF complex, the ability of guanine nucleotides to dissociate the wild-type and mutant binary complexes was directly investigated. Results are reported in Fig. 4 . Consistent with fluorescent experiments, these data indicate that the wild-type complex is completely dissociated by GDP concentration above 1 M, whereas both mutant complexes were barely affected by concentrations below 10 M. Both the T1184E and W1056E complexes were completely dissociated by 100 M GDP. Similar results were obtained with GTP-induced dissociation of the complexes.
Effect of cdc25
Mm Mutations on fos-luciferase Expression in NIH3T3 Fibroblasts-To examine whether the mutant GEFs could interfere with ras signaling in vivo, a fos-luciferase assay was used. pcDNA3-derived plasmids encoding full-length mutant CDC25
Mm were transiently cotransfected together with the fos-luciferase reporter plasmid into NIH3T3 cells. Both the W1056E and T1184E mutations were also introduced in a S1124V backbone, because mutations at this position have been shown to have a dramatic effect on CDC25 Mm structure and function. Namely, S1124V proteins had weak, temperature-sensitive guanine nucleotide exchange and dissociation activities in vitro and were unable to complement the yeast cdc25 mutant and to stimulate fos-luciferase activity. On the contrary, S1124A proteins displayed higher, more thermo-stable activity in vitro, were able to complement the yeast cdc25 mutant, and stimulated fos-luciferase activity in NIH3T3 cells twice as much as the wild-type CDC25
Mm protein (44) . Results obtained with mutants T1184E, T1184E/S1124V, W1056E, and W1056E/S1124V are reported in Fig. 5 . Under basal conditions (black bars), all mutants carrying the W1056E or the T1184E mutations reduced the level of ras-dependent fos-luciferase activity to ϳ30 -40% of the level observed in cells transfected with the empty pcDNA3 vector. On the contrary, expression of the recessive-negative W1056A or S1124V mutants did not significantly reduce fos-luciferase activity. The dominant-negative mutants displayed a very similar inhibitory effect when fos-luciferase activity was measured after PDGF stimulation with 100 ng/ml PDGF (white bars) or with 20% serum (striped bars). In serum-or PDGF-stimulated cells, the W1056E/ S1124V and T1184E/S1124V double mutants consistently displayed the strongest inhibitory effect, suggesting that the nature of the residue present at position 1124 may affect the penetrance of the W1056E and T1184E mutations. This interpretation is supported by the finding that when an alanine is introduced at position 1124, the effect of the W1056E mutation is abolished. In fact, the W1056E/S1124A double mutant is able to substitute for the CDC25 function in our standard yeast complementation assay (Table I) . Accordingly, fos-luciferase data obtained from NIH3T3 fibroblasts indicate that the W1056E/S1124A double mutant lost any dominant-negative property (Fig. 4) and now behaves similarly to wild type.
Ectopic Expression of CDC25 MmW1056E Strongly Reduces Proliferation of A10 Smooth Muscle Cells-The effect of a dominant-negative GEF on the proliferation potential and the ability to respond to PDGF was studied on a line of smooth muscle cells, A10. To this purpose a pcDNA3-derived plasmid expressing the mutant CDC25
MmW1056E gene was stably transfected in A10 cells as described under "Experimental Procedures." Genomic DNA was extracted from several transfected clones, integration of the pcDNA3-derived plasmid was confirmed by amplification of an internal CDC25
Mm fragment (Fig. 6A) , and expression of the transgene was confirmed by RT-PCR (Fig.  6B) . Morphology of representative cell lines is shown in Fig. 6 , C-F. No significant morphological changes were observed in clones transfected with GEF W1056E . The effects of GEF W1056E expression on growth rate and DNA synthesis (Fig. 7, A and B , respectively) were then tested and compared with that of the parental cell line transfected with the empty vector (cA10). Two representative cell lines expressing the GEF W1056E protein were grown in standard culture conditions as described under "Experimental Procedures," and their growth rate was compared with that of cA10. Both cell lines expressing the dominant-negative GEF W1056E proteins grew with similar kinetics showing a duplication time of 40 h as compared with the control cA10 cells that had a duplication time of 28 h. As shown in Fig.  7B , clones expressing GEF W1056E reported a dramatic reduction of DNA synthesis after PDFG stimulation. No significant reduction of DNA synthesis was observed in clones transfected with the recessive-negative mutant GEF W1056A .
DISCUSSION
The major role for guanine nucleotide exchange factors in ras activation seems that of facilitating nucleotide release. The preferential binding of GTP over GDP appears to be due to the higher intracellular GTP concentration (45) . The interaction between GEF and ras has to be sufficiently strong to displace the bound nucleotide and weak enough to allow entry of the nucleotide and disruption of the binary GEF⅐ras complex. Mutational events may alter this fine-tuned equilibrium, originating mutants with different properties. In this report we presented some biochemical and physiological properties of two dominant-negative mutants of the ras-specific GEF CDC25
Mm . Both mutants also form complexes with p21 ras in the presence of excess guanine nucleotides, i.e. conditions where no p21 ras ⅐GEF complex can be detected with wild-type GEF. A few different mechanisms may originate a dominant-negative GEF mutant. 1) The ternary complex (ras⅐GDP⅐GEF) remains stable, thus not allowing nucleotide exit and formation of the binary complex between nucleotide-free ras and GEF. 2) The mutant GEF binds nucleotide-free ras with increased affinity.
3) The binary complex between the mutant GEF and nucleotide-free ras has a diminished affinity for the incoming nucleotide. Both mechanisms 2 and 3 would result in an increased stabilization of the binary complex between nucleotidefree ras and GEF, allowing the formation of a stable complex under conditions where the complex would normally be disrupted by the presence of nucleotides. The experiments reported in Figs. 1B and 2 
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responsible for the dominant-negative properties of the W1056E and T1184E mutants, because the bound nucleotide is readily displaced by both mutant GEFs. Experiments reported in Figs. 3 and 4 clearly indicate that both mutations reduce the affinity of the binary complex for the incoming nucleotide, resulting in a similar stabilization of a binary complex. Taken together, these data suggest a rationale for the properties of the mutants.
The recent elucidation of the hSos⅐p21 ras complex (32) has started to clarify the molecular mechanism underlying GEF action. Firstly, a helical hairpin of hSos displaces the p21 ras -bound nucleotide by inducing a dramatic conformational change in the so-called "switch 1" region of ras. Because Sos does not directly occlude the nucleotide-binding site, except in the region where the terminal phosphate groups and the magnesium ion are bound, the incoming nucleotide can displace the GEF molecule by competing for the groups that bind the phosphate groups and the magnesium ion. Because of the extensive primary structure homology between the catalytic domains of Sos and CDC25 Mm , the general fold is likely to be conserved between the two GEF molecules. So, it is possible to speculate on the properties of the T1184E and W1056E mutants on the basis of the published structure of the hSos/ras complex (32) . To explain the biochemical dominant-negative properties of the W1056E and T1184E mutants we suggest that introduction of a glutamic acid at either position 1056 or 1184 allows formation of a novel salt bridge with a p21 ras residue involved in nucleotide binding. An attractive candidate is Lys 16 ; this residue takes part in binding to the GTP-␤ and -␥ phosphates, and its mutation to glutamine significantly reduces affinity of the mutant p21
ras for nucleotides, thus turning it into a dominantnegative mutant (46 16 close enough to interact. Local perturbations may easily be expected when amino acids with very different biochemical properties are substituted in critical positions. In particular, removal of the bulky tryptophan 1056 may leave an unflavored "cavity" which needs to be filled in by the substituting glutamate, thus bringing in close proximity residues that are relatively far away in the ras⅐wild-type GEF complex. In this scenario Glu 1056 or Glu 1184 in the mutated GEFs would compete exceedingly well with GTP-␤ and -␥ phosphates for binding to ras Lys 16 . As a result, the affinity of the mutant GEF⅐ras complex for guanine nucleotides would be lowered, resulting in the observed strong stabilization of the mutant GEF/p21 ras complex also in the presence of high nucleotide concentrations. In vivo this scenario is likely to be affected by other interfering factors. It has in fact recently been reported that both ras regulators and effectors, such as GTPase activating proteins, raf, and phosphatidyl-inositol-3 kinase (47, 48) may have an inhibitory effect on GEF-catalyzed guanine nucleotide exchange.
In mammalian cells expressing mutant GEF, the ras pathway is strongly down-regulated, as expected for a dominantnegative mutant. Down-regulation can be detected both under basal conditions (starved cells) and conditions of activation of the ras pathway brought about by either PDGF or serum stimulation. In vivo data (obtained both with the yeast complementation and fibroblast fos-luciferase assays) stress the importance of residue 1124 in modulating the penetrance of W1056E and T1184E mutations. Most notably, when an alanine is present at position 1124, the effect of the W1056E mutation is abolished. This behavior is not peculiar to the CDC25 Mm protein, because similar observations were made when the corresponding mutations were introduced in the yeast CDC25 protein (unpublished results).
Reduction of cell proliferation observed in CDC25
MmW1056E
transfected vascular smooth muscle cells further suggests the functional role of the GEF-negative mutant as an inhibitor of ras-dependent pathways. CDC25 MmW1056E intracellular expression specifically inhibited smooth vascular cell proliferation while having no effect on cellular morphology. The antiproliferative effect of the CDC25
Mm -negative mutant is consistent with previous studies in which the intracellular expression of either a dominant-negative form of ras or microinjection of neutralizing ras antibody exhibited a decrease in DNA synthesis in vascular smooth muscle cells (49, 50) . Proliferation of vascular smooth muscle cells constitutes the major pathological event responsible for the development of restenosis after percutaneous transluminal coronary angioplasty (51) . Several clinical studies have reported coronary restenosis after angioplasty to be as high as 45% within three to six months (52) , and no effective treatment for restenosis is presently available. The feasibility of regionally transferring plasmid DNA into vascular smooth muscle cells in vivo has been reported (53) . Transfection of a dominant-negative ras mutant significantly reduced rat neointima formation after vascular injury (5), thus suggesting the possibility that GEF-negative mutant transfection may offer a potential therapeutic approach to treat neointimal hyperplasia.
